Drugs /

melphalan

Back to Drugs List

Overview

Generic Name(s):
melphalan
Trade Name(s):
Alkerana, Sarkolysin, Melfalan, Alkeran, Melphalanum, and Evomela
NCI Definition [1]:
A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.

Clinical Trials

View Clinical Trials for melphalan

Melphalan has been investigated in 79 clinical trials, of which 66 are open and 13 are closed. Of the trials investigating melphalan, 4 are early phase 1 (2 open), 22 are phase 1 (18 open), 11 are phase 1/phase 2 (8 open), 33 are phase 2 (30 open), 1 is phase 2/phase 3 (1 open), 6 are phase 3 (6 open), and 2 are no phase specified (1 open).

Monosomy 7, del(5)(q10), and del(7)(q10) are the most frequent biomarker inclusion criteria for melphalan clinical trials.

Multiple myeloma, acute myeloid leukemia, and acute lymphoblastic leukemia are the most common diseases being investigated in melphalan clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Melphalan
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Melphalan
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating melphalan and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Alkeran, Alkerana, Melfalan, cb-3025, p-bis(beta-chloroethyl)aminophenylalanine, 4-(bis(2-chloroethyl)amino)phenylalanine, l-sarcolysin, melfalano, l-sarcolysin phenylalanine mustard, l-phenylalanine, 4-(bis(2-chloroethyl)amino)-, p-n-bis(2-chloroethyl)amino-l-phenylalanine, 1335, phenylalanine mustard, melphalan (product), l-sarcolysine, sarcolysin, mustard, phenylalanine, l-phenylalanine mustard, melphalan, melphalan (substance), 3-p-(di(2-chloroethyl)amino)-phenyl-l-alanine, l-sarcolysin, p-n,n-bis(2-chloroethyl)amino-l-phenylalanine, p-l-sarcolysin, 948, l-pam, 4-(bis(2-chloroethyl)amino)-l-phenylalanine, p-di-(2-chloroethyl)amino-l-phenylalanine, l-sarcolysin phenylalanine mustard, phenylalanine mustard, alanine nitrogen mustard, sarcoclorin, sarcolysin, p-di(chloroethyl)amino-l-phenylalanine, l-phenylalanine mustard, phenylalanine nitrogen mustard, wr-19813, 3-(p-(bis(2-chloroethyl)amino)phenyl)-l-alanine, melphalan [chemical/ingredient], Melphalanum, Sarkolysin, 4631, phenylalanine nitrogen mustard, l-phenylalanine mustard, melphalan, alanine nitrogen mustard, l-3-(p-(bis(2-chloroethyl)amino)phenyl)alanine, phenylalanine mustard, l-sarcolysine, 4-[bis(2-chloroethyl)amino]-l-phenylalanine, phenylalanine nitrogen mustard, Evomela
Drug Categories [2]:
Alkylating agents
NCIT ID [1]:
C633
SNOMED ID [1]:
C-78150

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.